Prostate cancer: To screen or not to screen?

Lancet Oncology

Volumn 1, Issue 1, 2000, Pages 17-24

  Neal, David E ^a   Donovan, Jenny L ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST OF ILLNESS; DECISION SUPPORT SYSTEM; DISEASE COURSE; HUMAN; MALE; MASS SCREENING; NEEDLE BIOPSY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNITED KINGDOM; UNITED STATES;

BIOPSY, NEEDLE; COST OF ILLNESS; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; GREAT BRITAIN; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; UNITED STATES;

EID: 0034285719     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00005-X     Document Type: Review

References (57)

1. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet. 355:2000;129-134.
2. Alexander FE, Anderson TJ, Brown HKM, et al. 14 years of follow-up from the Edinburgh randomised trial of breast cancer screening. Lancet. 353:1999;1903-1908.
3. Moss SM, Coleman DA, Chamberlain J, et al. 16-year mortality from breast cancer in the UK trial of early detection of breast cancer. Lancet. 353:1999;1909-1914.
4. Chamberlain J, Melia J, Moss S, et al. The diagnosis, management, treatment and costs of prostate cancer in England and Wales. NHS R&D HTA Programme: Health Technology Assessment 1997; 1 (3).
5. Selley S, Donovan JL, Faulkner A, et al. Diagnosis, management and screening of early localised prostate cancer. NHS R&D HTA Programme: Health Technology Assessment 1997; 1 (2).
6. Wasson JH, Sushman CC, Bruskewitz RC, et al. A structured literature review of treatment of localized prostate cancer. Arch Fam Med. 2:1993;487-493.
7. Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 119:1993;914-923.
8. Stewart-Brown S, Farmer A. Screening could seriously damage your health. BMJ. 314:1997;533.
9. UK experts advise against prostate cancer screening. Lancet. 349:1997;1-2.
10. Woolf SH. Should we screen for prostate cancer? BMJ. 314:1997;989-990.
11. Cadman D, Chambers L, Feldman W, et al. Assessing the effectiveness of community screening programs. JAMA. 251:1984;1580-1585.
12. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: WHO, 1968.
13. Peters TJ, Wildschut HIJ, Weiner CP. Epidemiologic considerations in screening. In: Wildschut HIJ, Weiner CP, Peters TJ, (eds). When to screen in obstetrics and gynaecology. London: WB Saunders Ltd, 1996.
14. Landis SH, Murray T, Bolden S, et al. Cancer statistics 1999. CA Cancer J Clin. 9:1999;8-13.
15. von Eschenbach A, Ho R, Murphy GP, et al. American Cancer Society Guidelines for early detection of prostate cancer. Cancer. 80:1997;1805-1807.
16. Jensen OM, Esteve J, Renard H. Cancer in the European Community and its member states. Eur J Cancer. 26:1990;1167-1256.
17. Office for National Statistics. 1993 Cancer statistics: registrations. London: HMSO, 1999.
18. Meikle AW, Smith JA. Epidemiology of prostate cancer. Urol Clin North Am. 17:1990;709-719.
19. Whitmore WF. Localized prostate cancer: management and detection issues. Lancet. 343:1994;1263-1267.
20. George NJR. Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet. i:1988;494-497.
21. Johansson J-E, Adami H-O, Anderson S-O, et al. Natural history of localised prostatic cancer. Lancet. 1:1989;799-803.
22. McGregor M, Hanley JA, Boivin J-F, et al. Screening for prostate cancer: estimating the magnitude of overdetection. Can Med Assoc J. 159:1998;1368-1372.
23. McCahy PJ, Harris CA, Neal DE. Breast and prostate cancerin the relatives of men with prostate cancer. Br J Urol. 78:1996;552-556.
24. Spitz MR, Currier RD, Fueger JJ, et al. Familial patterns of prostate cancer: a case-control analysis. J Urol. 146:1991;1305-1307.
25. McWhorter WP, Hernandez AD, Meikle AW, et al. A screening study of prostate cancer in high risk families. J Urol. 148:1992;826-828.
26. Coplen DE, Andriole GL, Yuan JJ, et al. The ability of systematic transectal ultrasound guided biopsy to detect prostate cancer in men with the clinical diagnosis of benign prostatic hyperplasia. J Urol. 146:1991;75-77.
27. Hammerer P, Huland H. Systematic sextant biopsies in 651 patients referred for prostate evaluation. J Urol. 151:1994;99-101.
28. Smith DS, Catalona WJ. The nature of prostate-cancer detected through prostate-specific antigen based screening. J Urol. 152:1994;1732-1736.
29. Labrie F. Screening and early hormonal treatmentof prostate cancer are accumulating strong evidence and support. Prostate. 43:2000;215-222. See also editorial by Metlin C. ibid. 223-24.
30. Reissigl A, Pointner J, Horninger W, et al. PSA-based screening for prostate cancer in asymptomatic younger males: pilot study in blood donors. Prostate. 30:1997;20-25.
31. Beemsterboer PMM, Kranse R, deKoning HJ, et al. Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Int J Cancer. 84:1999;437-441.
32. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA. 277:1997;1452-1455.
33. Schröder FH, van der Cruijsen-Koeter I, Koning HJ, et al. Prostate cancer detection at low prostate specific antigen. J Urol. 163:2000;806-812.
34. Collins MM, Ransohoff DF, Barry MJ. Early detectionof prostate cancer-serendipity strikes again. JAMA. 278:1997;1516-1519.
35. Maattanen L, Auvinen A, Stenman UH, et al. European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer. 79:1999;1210-1214.
36. Carter HB, Sauvageot J, Walsh PC, et al. Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J Urol. 157:1997;2206-2209.
37. Adolfsson J, Steineck G, Whitmore WF. Recent results of management of palpable clinically localized prostate cancer. Cancer. 72:1993;310-322.
38. Wasson JH, Sushman CC, Bruskewitz RC, et al. A structured literature review of treatment of localized prostate cancer. Arch Fam Med. 2:1993;487-493.
39. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 341:1999;1781-1788.
40. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
41. Litwin MS, Hays RD, Fink A, et al. Quality of life outcomes in men treated for localized prostate cancer. JAMA. 273:1995;129-135.
42. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 283:2000;354-360.
43. Volk RJ, Cass AR, Spann SJ. A randomized controlled trial of shared decision making for prostate cancer screening. Arch Fam Med. 8:1999;333-340.
44. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer. Part 1: evidence of the effects of screening in recent prostate cancer incidence, mortality and survival rates. J Natl Cancer Inst. 91:1999;1017-1024.
45. Farkas A, Schneider D, Perrotti M, et al. National trends in the epidemiology of prostate cancer, to 1994: evidence for the effectiveness of PSA screening. Urology. 52:1973;444-448.
46. Littrup PJ. Future benefits and cost-effectiveness of prostate carcinoma screening. Cancer. 80:1997;1864-1870.
47. Brawley OW. Prostate cancer incidence and patient mortality: the effects of screening and early detection. Cancer. 80:1997;1857-1863.
48. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer. Part 2: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 91:1999;1025-1032.
49. Etzioni R, Legler JM, Feuer EJ, et al. Cancer surveillance series: interpreting trends in prostate cancer. Part 3: quantifying the link between population PSA testing and recent declines in prostate cancer mortality. J Natl Cancer Inst. 91:1999;1033-1039.
50. Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G. Prostrate cancer screening in the Tyrol, Austria: experience and results. European journal of Cancer. 36:2000;1322-1335.
51. Batrtsch G. Data presented to the American Association of Genito-Urinary Surgeons; San Antonio, Texas, 2000.
52. Merrill RM, Feuer EJ, Warren JL, et al. Role of TURP in population-based prostate cancer incidence rates. Am J Epidemiol. 150:1999;848-860.
53. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate cancer mortality in England and Wales and the USA (research letter). Lancet. 335:2000;1788-1789.
54. Wolf A, Schorling JB. Preferences of elderly men for prostate specific antigen screening and the impact of informed consent. J Gerontol. 53A:1998;M195-200.
55. Bangma CH, Rietbergen JBW, Kranse R, et al. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol. 157:1997;2191-2196.
56. Neal DE, Donovan JL. Screening for prostate cancer. Ann Oncol. 9:1998;1289-1292.
57. Neal DE, Hamdy FC, Leung HY, et al. Unanswered questions in screening for prostate cancer. Eur J Cancer. 36:2000;1316-1321.